<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482209</url>
  </required_header>
  <id_info>
    <org_study_id>1.1.6</org_study_id>
    <nct_id>NCT00482209</nct_id>
  </id_info>
  <brief_title>Study of 400mcg Versus 800mcg Buccal Misoprostol Following Mifepristone 200mg for Abortion up to 63 Days Gestation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <brief_summary>
    <textblock>
      This double-blind, randomized study will compare the efficacy and acceptability of
      mifepristone 200mg followed in 36-48 hours by 400mcg or 800mcg of buccal misoprostol (i.e.,
      in the cheeks) for termination of pregnancy in women up to 63 days LMP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to provide answers to the following four questions:

        1. Is a regimen of medical abortion with mifepristone using 400mcg buccal misoprostol as
           effective and acceptable as using 800mcg buccal misoprostol up to 63 days since the last
           menstrual period (LMP)?

        2. Are the side effects with buccal use tolerable for women?

        3. Is buccal administration of misoprostol acceptable to women?

        4. When given a choice, do women prefer to take misoprostol at home or in the clinic?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for surgical completion for ongoing viable pregnancies at follow up visit (Study day 12-15) or for incomplete abortion at extended follow up visit (Study day (19-22).</measure>
    <time_frame>Study day 12-15 for ongoing viable pregnancies or Study day 19-22 for incomplete abortion at extended follow up visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side-effects, acceptability for women</measure>
    <time_frame>side effects and acceptability recorded at exit interview</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1220</enrollment>
  <condition>Induced Abortion</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg mifepristone followed by 400mcg misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg mifepristone followed by 800mcg misoprostol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone, misoprostol</intervention_name>
    <description>200mg mifepristone followed by 400mcg misoprostol 36-48 hours later</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mifepristone, misoprostol</intervention_name>
    <description>200mg mifepristone followed by 800mcg misoprostol 36-48 hours later</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18 years or over presenting for abortion services who consent to participate

          -  good general health

          -  assessed by a clinician to have an intrauterine pregnancy less than 64 days LMP on
             Study Day 1 and to be eligible for medical abortion

          -  Have ready access to a telephone and emergency transportation;

          -  Be willing to provide an address and/or telephone number for purposes of follow-up

        Exclusion Criteria:

          -  Conditions which contraindicate the use of mifepristone or misoprostol

          -  Women presenting for medical abortion who do not consent to participate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erica Chong, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamuna Tsereteli, MD, MSc, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maternity House #2</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternity House #4</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhordania Institute of Human Reproduction</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hocmon Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>http://www.gynuity.org</url>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>October 9, 2009</last_update_submitted>
  <last_update_submitted_qc>October 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Beverly Winikoff</name_title>
    <organization>Gynuity Health Projects</organization>
  </responsible_party>
  <keyword>mifepristone, misoprostol, medical abortion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

